[Federal Register Volume 66, Number 243 (Tuesday, December 18, 2001)]
[Notices]
[Pages 65214-65215]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-31048]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

[[Page 65215]]


ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Neurotrophic Components of the ADNF I Complex

Brenneman et al. (NICHD)
DHHS Reference No. E-209-01/0 filed 12 Sep 2001
Licensing Contact: Jonathan Dixon; 301/496-7056 ext. 270; 
<a href="/cdn-cgi/l/email-protection#c1a5a8b9aeafab81aea5efafa8a9efa6aeb7"><span class="__cf_email__" data-cfemail="c6a2afbea9a8ac86a9a2e8a8afaee8a1a9b0">[email protected]</span></a>

    Neuronal cell death has been associated with a variety of diseases 
and conditions, including Alzheimer's, AIDS-related dementia, 
Huntington's disease, and Parkinson's disease to name a few. Neuronal 
cell death has also been associated with developmental retardation and 
learning impairments that have lifelong effects on individuals 
diagnosed with these conditions.
    This invention discloses new Activity Dependent Neurotrophic Factor 
I (ADNF I) complex polypeptides. Previously, Activity Dependent 
Neurotrophic Factor (ADNF) polypeptides have been shown to prevent 
neuronal cell death. ADNF polypeptides are secreted by astroglial cells 
in the presence of vasoactive intestinal peptide (VIP). These new ADNF 
I complex polypeptides are effective for reducing neuronal cell death, 
for reducing oxidative stress, for reducing condition(s) associated 
with fetal alcohol syndrome in a subject, for enhancing learning and 
memory, both pre- and post-natally, and for other conditions.
    With these additional ADNF I complex polypeptides it will be easier 
to target specific receptors in different cell types and to 
individually tailor drug treatment regimes to those afflicted with 
neurodegenerative disorders.

Utilization of FPRL1 as a Functional Receptor by Serum Amyloid A 
(SAA)

Ji Ming Wang et al. (NCI)
DHHS Reference No. E-167-99/0 filed 22 Sep 1999 (PCT/US99/21770, WO 01/
21188)
Licensing Contact: Marlene Shinn; 301/496-7056 ext. 285; 
<a href="/cdn-cgi/l/email-protection#ed9e8584838380ad8289c3838485c38a829b"><span class="__cf_email__" data-cfemail="0f7c67666161624f606b2161666721686079">[email protected]</span></a>

    This technology identifies a means for modulating the interaction 
of Serum Amyloid A (SAA) with its functional receptor FPRL1. This 
modulation may have therapeutic applications in treating diseases such 
as infections, organ rejection, rheumatoid arthritis, atherosclerosis, 
neoplasms, and amyloidosis. The SAA, an acute phase protein, is 
normally present in serum but increases by 1,000 fold in systemic 
inflammatory conditions and is associated with leukocyte migration in 
these disease states. This technology identifies various means to 
modulate the association of SAA and FPRL1 in a SAA-FPRL1 complex or 
method of identifying agents that associate with the complex. It is 
available for immediate licensing and research collaborations via a 
Cooperative Research and Development Agreement (CRADA).

    Dated: December 10, 2001.
Jack Spiegel,
Director, Division of Technology, Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 01-31048 Filed 12-17-01; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>